Document Type

Conference Proceeding

Publication Date


Publication Title

Developmental Medicine and Child Neurology


Introduction: The effects of incobotulinumtoxinA on upper limb (UL) spasticity-related pain (SRP) over multiple treatment cycles (ICs) in children/adolescents (C/As) with cerebral palsy (CP) were analyzed using pooled data from two prospective phase 3 trials.

Patients and methods: C/As aged 2–17 years with CP-associated UL spasticity received incobotulinumtoxinA for 4 ICs. SRP was assessed with the Questionnaire on Pain caused by Spasticity (QPS) using C/A- (direct or via interviewer) and parent/caregiver (P/C)-completed UL modules. The pain population included all C/As with a key QPS item score >0 at baseline; post-baseline scores of 0 indicated complete pain relief.

Results: Data from 155 C/As and 444 P/Cs with data for at least one key QPS item were included. UL general SRP was reported by 69 C/As at baseline; 39.7%/41.8% of patients treated with incobotulinumtoxinA were pain-free by week 4 of IC1/IC4 (p

Conclusion: In addition to muscle tone regulation, incobotulinumtoxinA provided sustained pain relief across multiple ICs for children with CP and UL SRP, even when they were engaged in demanding tasks.




Suppl 3

First Page



34th Annual Meeting of the European Academy of Childhood Disability, EACD 2022, May 18-21, 2022, Barcelona, Spain.

Toxins 6th International Conference, July 27-30, 2022, New Orleans, LA. Toxicon. 2022 Jul;214(Suppl 1):S24.